Fredun Pharmaceuticals Ltd539730Corporate

Pharmaceuticals Latest results: Jun 2026 7 quarters of data

₹1,221.60

MCap ₹611 Cr · P/E 14.2

Fredun Pharmaceuticals Ltd — Stock analysis & AI research Fredun Pharmaceuticals Ltd — Multibagger AI analysis Fredun Pharmaceuticals Ltd — Live exchange announcements

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹228 Cr

Sales · Jun 2026

+90.2% YoY

₹33 Cr

Operating Profit · Jun 2026

+92.6% YoY

14.3%

OPM % · Jun 2026

+0.7% YoY

₹13 Cr

Net Profit · Jun 2026

+87.6% YoY

₹23.82

EPS · Jun 2026

+399.4% YoY

📝 Fredun Pharmaceuticals Ltd — results explained

Quarter ended June 2026 (Q1 FY27)

Fredun Pharmaceuticals Ltd reported revenue of ₹228 crore for the quarter ended June 2026 (Q1 FY27), up 90.2% from ₹120 crore in the same quarter last year, and up 7.2% sequentially over the March 2026 quarter.

Net profit rose 87.6% year-on-year to ₹13 crore, from ₹7 crore. Earnings per share (EPS) came in at ₹23.82.

Operating profit stood at ₹33 crore — an operating margin (OPM) of 14.3%, compared with 14.2% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Fredun Pharmaceuticals Ltd posted revenue of ₹639 crore, with a net profit of ₹37 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹747 crore with a net profit of ₹43 crore.

Valuation snapshot

At the current price of ₹1,221.60, 539730 has a market capitalisation of ₹611 crore and a trailing P/E of about 14.2.

Within the Pharmaceuticals industry, it is the 12th-largest of the 82 companies we track by market value.

Shareholding pattern

As of Jul 2026, promoters held 44.57%, foreign institutional investors (FIIs) 1.06%, domestic institutional investors (DIIs) 2.94%, public shareholders 51.43% of Fredun Pharmaceuticals Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹611 Cr

Current Price ?

₹1,221.6

P/E ?

14.16below ind

Industry P/E ?

22.40

P/B ?

2.20

P/S ?

0.82

P/FCF ?

-9.85

Enterprise Value ?

₹833 Cr

EV/EBITDA ?

7.59

PEG ?

N/A

Earnings Yield ?

11.9%

Dividend Yield ?

0.02%

Profitability & Returns

Sales (TTM) ?

₹747 Cr

OPM ?

14.7%

Profit after tax (TTM) ?

₹43 Cr

EPS (TTM) ?

₹86.26

ROCE ?

21.0%

ROE ?

15.5%

ROA ?

6.7%

Growth

Sales — latest qtr ?

₹228 Cr

PAT — latest qtr ?

₹13 Cr

YoY qtr sales growth ?

90.2%

YoY qtr profit growth ?

87.6%

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹222 Cr

Debt to Equity ?

0.80

Interest Coverage ?

2.1

Current Ratio ?

N/A

Ownership

Promoter holding ?

44.57%

Change in promoter holding ?

1.51%

Pledged percentage ?

N/A

Market

Return 3 months ?

40.1%

Return 6 months ?

122.0%

🗓️ Quarterly results (7 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	0	167	120	145	161	213	228	+90.2%	+7.2%
Operating Profit	0	17	17	22	26	29	33	+92.6%	+12.9%
Other Income	0	0	0	0	0	0	0	—	—
Interest	0	8	7	8	11	14	9	+23.1%	-38.4%
Depreciation	0	2	1	2	2	3	4	+257.1%	+19.0%
Profit Before Tax	0	7	9	13	14	11	21	+128.4%	+86.8%
Net Profit	0	6	7	9	10	11	13	+87.6%	+19.4%
EPS	0.00	4.23	4.77	6.64	6.51	6.57	23.82	+399.4%	+262.6%
OPM %	—	10.2%	14.2%	15.2%	16.1%	13.6%	14.3%	+0.7%	+5.1%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	Prev FY	FY26	TTM	YoY %
Sales	—	₹639 Cr	₹747 Cr	—
Operating Profit	—	₹94 Cr	₹110 Cr	—
OPM %	—	14.71%	14.69%	—
NPM %	—	5.79%	5.77%	—
Other Income	—	₹0 Cr	₹0 Cr	—
Depreciation	—	₹8 Cr	₹11 Cr	—
Interest	—	₹40 Cr	₹42 Cr	—
EBIT	—	₹86 Cr	₹99 Cr	—
PBT	—	₹47 Cr	₹59 Cr	—
Tax	—	—	₹7 Cr	—
Net Profit	—	₹37 Cr	₹43 Cr	—
EPS	—	₹24.49	₹43.54	—
Material Cost	—	—	₹180 Cr	—
Employee Cost	—	—	₹7 Cr	—
Extraordinary Items	—	—	—	—

🏛️ Balance Sheet (latest 2 periods)

Metric	Mar 2025	Mar 2026	% Chg
Equity Capital	5	5	+0.0%
Reserves	137	273	+99.3%
Borrowings	167	222	+32.9%
Other Liabilities	179	142	-20.7%
Total Liabilities	487	642	+31.8%
Fixed Assets	53	118	+122.6%
CWIP	0	0	—
Investments	2	2	+0.0%
Other Assets	433	522	+20.6%
Total Assets	487	642	+31.8%

💧 Cash Flow (latest 2 periods)

Metric	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	-17	12	+170.6%
Cash from Investing Activity	-6	-74	-1133.3%
Cash from Financing Activity	27	121	+348.1%
Net Cash Flow	4	60	+1400.0%
Free Cash Flow	-23	-62	-169.6%
CFO/OP	-32%	13%	+140.6%

➗ Ratios (latest 2 periods)

Metric	Mar 2025	Mar 2026	% Chg
Debtor Days	142	53	-62.7%
Inventory Days	267	219	-18.0%
Days Payable	161	71	-55.9%
Cash Conversion Cycle	248	201	-19.0%
Working Capital Days	76	78	+2.6%
ROCE %	—	21%	—

👥 Shareholding (latest 4 periods)

Metric	Dec 2025	Mar 2026	Jun 2026	Jul 2026	% Chg
Promoters	43.06%	44.17%	44.57%	44.57%	+0.0%
FIIs	0.46%	1.06%	1.06%	1.06%	+0.0%
DIIs	3.48%	2.83%	2.94%	2.94%	+0.0%
Public	53.00%	51.94%	51.45%	51.43%	-0.0%
No. of Shareholders	8,765	8,338	8,903	9,598	+7.8%

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 82 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SUDEEPPHRM Sudeep Pharma	₹1,033.30	11,671	63.3	675	184	34.6%	27.3%	—	—	26.6%	30.9%
2	SPARC Sun Pharma	₹185.08	6,006	3.8	1,909	1,584	84.7%	83.0%	2512.3%	553.9%	314.1%	59.9%
3	GUJTHEM Gujarat Themis	₹412.60	5,370	92.3	173	48	47.3%	27.8%	8.6%	-6.1%	21.6%	23.0%
4	539997 Kwality Pharmaceuticals	₹2,652.10	3,525	34.0	553	81	24.4%	14.6%	35.7%	71.8%	46.3%	113.5%
5	524632 Shukra Pharmaceuticals	₹80.95	2,403	99.9	75	36	65.0%	48.2%	74.0%	130.1%	336.4%	1359.2%
6	FERMENTA Fermenta Biotech	₹475.00	1,362	21.4	501	64	18.9%	12.7%	—	—	-17.9%	-30.6%
7	506414 Fermenta Biotech	₹552.60	1,313	27.2	511	59	17.6%	11.5%	11.9%	-6.6%	-10.4%	-56.7%
8	AHCL Anlon Healthcare	₹20.20	1,074	—	—	—	—	—	—	—	163.0%	133.3%
9	541096 Bharat Parenterals	₹1,525.00	1,062	—	323	-30	3.3%	-9.3%	1.5%	37.5%	-19.2%	-309.6%
10	540737 Shree Ganesh	₹796.30	855	66.2	99	15	31.4%	15.6%	0.7%	-23.0%	-41.8%	-67.5%
11	AMANTA Amanta Healthcare	₹197.75	768	52.5	291	15	20.4%	5.0%	—	—	5.4%	-5.6%
12	539730 Fredun Pharmaceuticals	₹827.85	611	10.3	747	44	14.7%	5.9%	40.1%	90.0%	90.2%	88.1%
13	500422 Transchem Ltd-$	₹38.00	474	10.8	—	4	—	—	-100.0%	-17.8%	-100.0%	186.3%
14	HALEOSLABS Haleos Labs	₹1,525.00	461	21.0	324	15	12.6%	4.7%	-3.2%	-4.9%	-11.6%	-58.0%
15	524731 Jenburkt Pharmaceuticals	₹865.75	404	11.6	170	33	23.6%	19.4%	11.8%	6.1%	-1.4%	-26.4%
16	543616 Trident Lifeline	₹279.85	364	14.0	134	24	24.6%	17.9%	—	—	42.6%	44.2%
17	512600 Astal Laboratories	₹75.00	308	32.3	170	10	8.8%	5.7%	142.9%	-9.0%	56.0%	77.4%
18	524828 BDH Industries	₹336.80	300	16.6	100	12	15.3%	11.7%	44.3%	16.6%	20.2%	48.8%
19	500009 Ambalal Sarabhai	₹38.73	297	21.9	206	14	7.1%	6.6%	3.1%	261.1%	8.0%	-51.6%
20	532039 Zenotech Laboratories	₹64.90	263	—	45	-3	17.0%	-5.6%	1.3%	-119.2%	10.1%	-146.0%
21	531739 Gennex Laboratories	₹13.87	255	19.0	183	21	14.4%	11.3%	24.9%	15.5%	16.6%	-6.9%
22	524790 Everest Organics	₹159.20	252	29.4	191	5	10.3%	2.8%	23.0%	527.7%	-10.0%	-21.1%
23	530163 Kerala Ayurveda	₹310.20	225	—	125	-26	-14.9%	-20.8%	9.0%	-16.8%	-21.3%	-477.8%
24	531569 Sanjivani Paranteral	₹199.95	214	32.7	66	7	15.3%	11.3%	-7.6%	-14.4%	8.8%	32.7%
25	524636 Oxygenta Pharmaceutical	₹32.25	195	—	135	-14	-5.9%	-10.1%	3.3%	-70.8%	144.5%	65.6%

❓ Frequently asked questions

What was Fredun Pharmaceuticals Ltd's revenue in Q1 FY27?

What was Fredun Pharmaceuticals Ltd's net profit in Q1 FY27?